By Alex Lash
Like many of its drug-industry brethren, Bayer AG's Bayer HealthCare AG says it's ready to find good homes...
Drug firms need to find good homes for hundreds of early-stage experimental compounds that ideally they could claw back once new developers demonstrate proof-of-concept. New project financing funds are clamoring for those assets, but first they must convince LPs to invest in unproven financing models, deal with pharma's accounting demands, and negotiate deals with asset-holders that will provide a decent return.
By Alex Lash
Like many of its drug-industry brethren, Bayer AG's Bayer HealthCare AG says it's ready to find good homes...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.